Oxford Vacmedix
UK - OxfordBiotechnology
Focus: Oxford Vacmedix is a UK-based cancer vaccine biotechnology company focused on immunotherapy approaches to oncology and infectious diseases. The company is in Series B stage with a lean pipeline anchored on early-stage development.
Profile data last refreshed 23h ago · AI intelligence enriched 1w ago
Funding Stage
SERIES B
Open Jobs
0
About Oxford Vacmedix
AI assessmentNot HiringNo open roles listed right now. Follow Oxford Vacmedix to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
OVM-200
Prostate CancerClinical Trials (1)
NCT05104515First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
Phase 1Help build intelligence for Oxford Vacmedix
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.